---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-279068"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T05:29:25.649560+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Revolution Medicines reports Q3 net loss $73.3M; cash $655M; clinical trials progressing

## Summary
- Net loss of $73.3M for Q3 2022, up from $52.9M in Q3 2021; revenue $3.4M from Sanofi collaboration.
- Cash, equivalents, and marketable securities $655M as of Sep 30, 2022, boosted by July 2022 equity offering of $264.5M gross.
- Phase 1/1b trials ongoing for RMC-6236 (RAS MULTI) and RMC-6291 (KRAS G12C); first data expected in 2023.
- RMC-9805 (KRAS G12D) first patient dosing expected mid-2023.
- Full-year 2022 GAAP net loss guidance reiterated at $260M-$280M; cash runway through 2024.

## SEC filing metadata
- accession: 0001193125-22-279068
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000119312522279068/0001193125-22-279068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000119312522279068/d418464d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-279068
- JSON: https://secwatch.observer/filing/0001193125-22-279068.json
- Plain text: https://secwatch.observer/filing/0001193125-22-279068.txt

## Key facts
- Earnings Releases
  Revolution Medicines, Inc. reported financial results for quarter ended September 30, 2022.
  - Period: quarter ended September 30, 2022
  - Result: reported results
  source text: On November 7, 2022, Revolution Medicines, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628171/000119312522279068/0001193125-22-279068-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.